Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Michelle S. Ginsberg, MD"'
Autor:
Andreas Rimner, MD, Prasad S. Adusumilli, MD, Michael D. Offin, MD, Stephen B. Solomon, MD, Etay Ziv, MD, Sara A. Hayes, MD, Michelle S. Ginsberg, MD, Jennifer L. Sauter, MD, Daphna Y. Gelblum, MD, Annemarie F. Shepherd, MD, David M. Guttmann, MD, Jordan E. Eichholz, MS, Zhigang Zhang, PhD, Erika Ritter, BS, Phillip Wong, PhD, Afsheen N. Iqbal, MD, Robert M. Daly, MD, Azadeh Namakydoust, MD, Henry Li, BS, Megan McCune, BS, Emily H. Gelb, BS, Neil K. Taunk, MD, Donata von Reibnitz, MD, Neelam Tyagi, PhD, Ellen D. Yorke, PhD, Valerie W. Rusch, MD, Marjorie G. Zauderer, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 1, Pp 100440- (2023)
Introduction: Single-agent monoclonal antibody therapy against programmed death-ligand 1 (PD-L1) has modest effects in malignant pleural mesothelioma. Radiation therapy can enhance the antitumor effects of immunotherapy. Nevertheless, the safety of c
Externí odkaz:
https://doaj.org/article/8350f1d8ba0d4d41ad97457d20805a67
Autor:
Kathryn C. Arbour, MD, Eusebio Manchado, PhD, Matthew J. Bott, MD, Linda Ahn, NP, Yosef Tobi, BA, Andy Ai Ni, Helena A. Yu, MD, Alyssa Shannon, BA, Marc Ladanyi, MD, Victoria Perron, BS, Michelle S. Ginsberg, MD, Amanda Johnson, BA, Andrei Holodny, MD, Mark G. Kris, MD, Charles M. Rudin, MD, PhD, Piro Lito, MD, PhD, Neal Rosen, MD, PhD, Scott Lowe, PhD, Gregory J. Riely, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100256- (2022)
Introduction: Somatic KRAS mutations occur in 25% of patients with NSCLC. Treatment with MEK inhibitor monotherapy has not been successful in clinical trials to date. Compensatory activation of FGFR1 was identified as a mechanism of trametinib resist
Externí odkaz:
https://doaj.org/article/08ab67b4ab914fc8921cb36a60feebfe